ethyl 2-bromo-4,4-dimethyl-3-oxopentanoate | 81569-29-1

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 酮酸及其衍生物
• 英文名称: ethyl 2-bromo-4,4-dimethyl-3-oxopentanoate
• 英文别名: 2-bromo-4-tert-butyl-3-oxobutanoate；α-Bromo-pivaloyl acetic acid ethyl ester；α-Bromo-pivaloylacetic acid ethyl ester
• CAS: 81569-29-1
• 化学式: C₉H₁₅BrO₃
• 分子量: 251.12
• InChiKey: WOGMPMSERLXZKO-UHFFFAOYSA-N

物化性质

• 沸点：
  259.2±20.0 °C(Predicted)
• 密度：
  1.312±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  13
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.78
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  ethyl 2-bromo-4,4-dimethyl-3-oxopentanoate 在 氢氧化钾 、 亚膦酸 、 sodium nitrite 作用下， 以 乙醇 、 水 为溶剂， 反应 2.5h， 生成 4-t-butylthiazole-5-carboxylic acid
  参考文献：
  名称：

  Barton, Anne; Breukelman, Stephen P.; Kaye, Perry T., Journal of the Chemical Society. Perkin transactions I, 1982, p. 159 - 164

  摘要：

  DOI：
• 作为产物：
  描述：

  特戊酰基乙酸乙酯 在 草酰溴 、 二甲基亚砜 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 以97%的产率得到ethyl 2-bromo-4,4-dimethyl-3-oxopentanoate
  参考文献：
  名称：

  用二甲基亚砜和草酰溴溴化烯烃，炔烃和酮的高效方法

  摘要：

  摘要 据报道，DMSO和草酰溴的配对是用于各种烯烃，炔烃和酮的高效溴化试剂。这种溴化方法显示出显着的优势，例如条件温和，成本低，反应时间短，在大多数情况下提供优异的收率，并且是制备二溴化物和α-溴代酮的极具吸引力的替代方法。 据报道，DMSO和草酰溴的配对是用于各种烯烃，炔烃和酮的高效溴化试剂。这种溴化方法显示出显着的优势，例如条件温和，成本低，反应时间短，在大多数情况下提供优异的收率，并且是制备二溴化物和α-溴代酮的极具吸引力的替代方法。

  DOI：

  10.1055/s-0037-1609560

文献信息

• Asymmetric Organocatalytic Cyclopropanation - Highly Stereocontrolled Synthesis of Chiral Cyclopropanes with Quaternary Stereocenters
  作者：Xavier Companyó、Andrea-Nekane Alba、Francisco Cárdenas、Albert Moyano、Ramon Rios

  DOI：10.1002/ejoc.200900209

  日期：2009.6

  A convenient and novel domino reaction for the synthesis of highly functionalized cyclopropanes is reported. The addition of 2-bromoketo esters to a variety of ?,?-unsaturated aldehydes catalyzed by secondary amines leads to chiral cyclopropanes with three stereogenic carbon atoms, including one quaternary stereocenter, in a highly stereocontrolled fashion.

  报告了一种用于合成高度官能化环丙烷的方便且新颖的多米诺骨牌反应。将 2-溴酮酯加成到由仲胺催化的各种α,β-不饱和醛中，以高度立体控制的方式产生具有三个立体碳原子（包括一个季立体中心）的手性环丙烷。
• Thiazole derivatives
  申请人：Hoffmann-La Roche Inc.

  公开号：US06344562B1

  公开（公告）日：2002-02-05

  Compounds of the formula: as well as pharmaceutically usable salts and esters thereof, wherein R1, R2 and R3 have the significance ascribed herein, inhibit binding of adhesive proteins to the surface of different types of cell and accordingly influence cell-cell and cell-matrix interactions. These compounds can be used in the form of pharmaceutical preparations for the control or prevention of neoplasms, tumor metastasing, tumor growth, osteoporosis, Paget's disease, diabetic retinopathy, macular degeneration, restenosis following vascular intervention, psoriasis, arthritis, fibrosis, kidney failure, as well as infection caused by viruses, bacteria or fungi.

  该公式的化合物：以及其药用盐和酯，其中R1、R2和R3具有在此规定的意义，抑制粘附蛋白质与不同类型细胞表面的结合，从而影响细胞-细胞和细胞-基质相互作用。这些化合物可以用作制药制剂的形式，用于控制或预防肿瘤、肿瘤转移、肿瘤生长、骨质疏松症、帕盖特病、糖尿病视网膜病变、黄斑变性、血管介入后再狭窄、银屑病、关节炎、纤维化、肾功能衰竭，以及由病毒、细菌或真菌引起的感染。
• Nf-kb activation inhibitors
  申请人：Muto Susumu

  公开号：US20060089395A1

  公开（公告）日：2006-04-27

  A medicament having inhibitory activity against NF-κB activation which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein A represents hydrogen atom or acetyl group, E represents a 2,5-di-substituted or a 3,5-di-substituted phenyl group, or a monocyclic or a fused polycyclic heteroaryl group which may be substituted, provided that the compound wherein said heteroaryl group is circle around (1)} a fused polycyclic heteroaryl group wherein the ring which binds directly to —CONH— group in the formula (I) is a benzene ring, circle around (2)} unsubstituted thiazol-2-yl group, or circle around (3)} unsubstituted benzothiazol-2-yl group is excluded, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —CONH-E wherein E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —CONH-E wherein E has the same meaning as that defined above.

  一种药物具有抑制NF-κB活化作用，其包括以下通式(I)所表示的化合物或其药学上可接受的盐、水合物和溶剂化物作为活性成分，其中A代表氢原子或乙酰基，E代表2,5-二取代或3,5-二取代苯基或单环或融合的多环杂环芳基，其可以被取代，但在所述杂环芳基是圆圈(1)}在公式(I)中直接结合—CONH—基团的环为苯环的融合多环杂环芳基，圆圈(2)}未取代的噻唑-2-基团，或者圆圈(3)}未取代的苯并噻唑-2-基团时，不包括该化合物，环Z代表一个芳香烃，除了由公式—O-A所表示的基团外，它也可以有一个或多个取代基，其中A具有与上述定义相同的含义，公式—CONH-E所表示的基团E具有与上述定义相同的含义。
• Inhibitors against the activation of ap-1 and nfat
  申请人：Muto Susumu

  公开号：US20060100257A1

  公开（公告）日：2006-05-11

  A medicament inhibiting the activation of AP-1 which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above.

  一种药物，抑制AP-1的激活，其活性成分为以下通式（I）所表示的化合物或其药学上可接受的盐、水合物或溶剂化物中所选的一种，其中X代表连接基，其主链中的原子数为2至5（该连接基可以被取代），A代表氢原子或乙酰基，E代表芳基或取代的杂芳基，环Z代表芳烃，除了由式—O-A所表示的基团外，可能还有一个或多个取代基，其中A具有上述定义的相同含义，由式—X-E所表示的基团中，X和E的每一个具有上述定义的相同含义，或者是一个杂芳烃，可能还有一个或多个取代基，其中A具有上述定义的相同含义，由式—X-E所表示的基团中，X和E的每一个具有上述定义的相同含义。
• Medicament for treatment of diabetes
  申请人：Muto Susumu

  公开号：US20060111409A1

  公开（公告）日：2006-05-25

  A medicament for preventive and/or therapeutic treatment of diabetes or complications of diabetes which comprises as an active ingredient a substance selected from the group consisting of a compound represented by the following general formula (I) and a pharmacologically acceptable salt thereof, and a hydrate thereof and a solvate thereof: wherein X represents a connecting group whose number of atoms in the main chain is 2 to 5 (said connecting group may be substituted), A represents hydrogen atom or acetyl group, E represents an aryl group which may be substituted or a hetero aryl group which may be substituted, ring Z represents an arene which may have one or more substituents in addition to the group represented by formula —O— A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above, or a heteroarene which may have one or more substituents in addition to the group represented by formula —O-A wherein A has the same meaning as that defined above and the group represented by formula —X-E wherein each of X and E has the same meaning as that defined above.

  一种用于预防和/或治疗糖尿病或糖尿病并发症的药物，其活性成分为以下通式（I）所表示的化合物或其药学上可接受的盐、水合物或溶剂化物之一： 其中，X代表主链中原子数为2到5的连接基（该连接基可以被取代），A代表氢原子或乙酰基，E代表可以被取代的芳基或杂环芳基，环Z代表可以具有一个或多个取代基的芳基，除了由公式—O—A所表示的基团外，该芳基可以具有公式—X-E所表示的基团，其中每个X和E的含义与上述定义相同，或者可以具有一个或多个取代基的杂环芳基，除了由公式—O—A所表示的基团外，该杂环芳基可以具有公式—X-E所表示的基团，其中每个X和E的含义与上述定义相同。